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Previously we demonstrated that human small-cell lung cancer (SCLC) seems to univer-
sally express the vasopressin gene, and this leads to the presence of a cell surface marker
representing the entire pro-hormone precursor. In this study, we show this marker can
be targeted with MAG-1, a mouse monoclonal antibody against a C-terminal moiety on
pro-vasopressin. In vitro targeting of cell lines derived from primary and recurrent dis-
ease demonstrates attachment of antibody to the cell surface followed by internalization.
In vivo targeting with 99Tc-labeled Fab fragments of MAG-1 shows selective attachment
to xenografts. In vivo treatment of tumors from classical cell line, NCI H345, with either
~1.65 mCi (~1.65 mg)/kg body weight (BW) of 90Yttrium-labeled MAG-1, or ~1.65 mg/kg
BW native MAG-1, delivered every second day for 6 days produced similar reductions in
the growth rate to ~50% (p<0.03).When dosing with native MAG-1 was escalated to daily
amounts of ~3.3 mg/kg BW over 16 days, tumor growth rates fell to ~33% of saline controls
(p<0.005). Examination of tumors treated with this higher dosing demonstrated the pres-
ence in several of extensive apoptosis. Normal tissues seemed to be unaffected. A larger
dosage of MAG-1 (~6.6 mg/kg BW) given daily for 14 days was used to treat xenografts of
the variant cell line NCI H82 representing recurrent disease.This treatment decreased the
rate of increase in tumor size by half, and doubling time ~3-fold. Increases in cleaved PARP
supported increased apoptosis with antibody treatment.We believe these data provide evi-
dence that the growth rate of SCLC tumors can be extensively reduced by treatment with
MAG-1 antibody, and that a humanized form of this antibody could, in future, be potentially
used for targeting therapy onto recurrent SCLC in patients.
Keywords: small-cell lung cancer, targeted treatment, GRSA surface marker, pro-vasopressin, MAG-1 antibody,
recurrent disease, STEPS concept
INTRODUCTION
While some reduction in the incidence of lung cancer has occurred
in recent times, there are still an expected 40,000 new cases
of small-cell lung cancer (SCLC) per year in the United States.
Present treatments of SCLC generally involve high-dose combi-
nation chemotherapy with or without radiation therapy (1–11).
Although there is a high initial response rate to these treatments,
and long-term survival in up to 10% of all cases (8, 9, 11), average
life expectancy is increased by only 8–15 months. While about 80%
of these newly diagnosed SCLC patients respond to chemotherapy,
remission generally lasts only 3–6 months. Unfortunately, there is
no effective therapy to treat recurrent disease because it is resistant
to available approaches, including chemotherapies.
Small-cell lung cancer commonly expresses neuropeptides and
one of us has advanced the STEPS concept of neuropeptide pro-
duction by these tumors (12), which emphasizes process over
origin and thus serves as a counter-balance to the APUD con-
cept of Pierce (13). STEPS points to neuropeptides arising as
part of the oncogenic process (rather than being present in cells
from which tumors originate), and therefore reflects the now gen-
erally recognized “autocrine growth loop” involving peptides as
a key survival strategy. We, and others, have demonstrated that
vasopressin is one such neuropeptide (14–23). It is expressed by
both primary and recurrence SCLC together with all four vaso-
pressin receptors (19, 21), and has tumor growth modulating
activities (18, 19, 23). Clinical evidence of ectopic production
only occurs in 10–15% of cases, but expression of the vaso-
pressin gene seems to be universal (20, 24–29). Tumor expres-
sion uniquely gives rise to some unprocessed precursor becom-
ing a component of the plasma membrane, and this marker
can be targeted with antibodies (30, 31). One such antibody is
MAG-1, a mouse monoclonal antibody raised against the 18-
mer C-terminal structure of the precursor (31). MAG-1 is of
the IgG1 sub-class, and recognizes the marker in over 90% of
SCLC tumors, and in all long-term cultures examined (20, 31,
32). MAG-1 has the ability to shrink and almost destroy both
estrogen-responsive and triple-negative breast cancer xenografts
(33). In the current study, we examined the effects of MAG-1
and 90Yttrium-labeled MAG-1, on the growth of human tumor
xenografts derived from the classical cell line NCI H345, and the
variant cell line, NCI H82, representing respectively, primary and
recurrent disease.
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MATERIALS AND METHODS
TUMOR CELLS
The human SCLC cell lines NCI H345 and NCI H82 were obtained
from ATCC (American Type Culture Collection, Rockville, MD,
USA) and maintained in DMEM medium (Mediatech, Inc., Hern-
don, VA, USA), containing 10% fetal bovine serum (Atlanta Bio-
logicals) at 37°C, in an atmosphere of 5% CO2 with medium
changes every 3 and 4 days. These cultures were grown in tissue
culture flasks at densities from 1 to 5× 105 cells/ml. Since NCI H82
cells representing recurrent disease was the chief subject of inves-
tigations reported here, samples of the NCI H82 cells used here
were sent back to ATCC at the completion of studies and verified
by that body to indeed be representative of that long-term culture.
ANTIBODIES
The mouse monoclonal antibody, MAG-1, was generated against
an 18-mer C-terminal segment of human pro-vasopressin (31–
33), and MAG-1 is the subject of a patent by Woomera Therapeu-
tics Inc. (34). MOPC21 is of the same IgG1 sub-class as MAG-1,
but is a ubiquitous antibody produced by a mouse myeloma cell
line (35). For this study, both antibodies were purified from cul-
ture by Protein A affinity chromatography (Bio-Xcell, Lebanon,
NH, USA). For generation of radiolabeled form of MAG-1, the
antibody was first chelated by reaction at pH 8.3 overnight with
CHX-A′′-DTPA reagent in 10-fold excess (36). DTPA-modified
antibodies were then reacted with 90Yttrium chloride (Amersham
>100 Ci/µmol, >500 mCi/ml) and 90Yttrium-labeled products
isolated by Sephadex G-25 chromatography. Mouse polyclonal
antibodies were generated against the 18-mer C-terminal segment
of mouse pro-vasopressin (VQLAGTRESVDSAKPRVY), which
has only 50% homology with the human C-terminus. The peptide
was coupled to thyroglobulin using glutaraldehyde and used to
immunize mice mixed 1:1 with Freund’s adjuvant. A preparation
of rabbit polyclonal antibodies for measuring intact and 89-kDa
cleaved PARP was purchased from Cell Signaling Technology
(#9542, Danvers, MA, USA).
CONFOCAL MICROSCOPY
Small-cell lung cancer cells (NCI H345 and NCI H82) were seeded
(104) onto glass coverslips and allowed to recover for 24 h at
37°C. The cells were treated with a paraformaldehyde fixative
buffer, permeabilized with 0.05% NP40 (Sigma-Aldrich Chemi-
cal Co.) and non-specific staining blocked with a gelatin buffer.
They were then incubated with MAG-1 antibody (or MOPC anti-
body control) diluted in PBS containing 0.1% BSA, washed five
times with buffer, and then incubated with Alexa Fluor 488 goat
anti-mouse secondary antibody (Molecular Probes) for 1 h, fol-
lowing manufacturer recommendations. Finally, cells were washed
(×5) with 1% BSA in PBS, the nuclei of the cells sometimes
stained using DAPI, cells post-fixed with 4% paraformaldehyde
and mounted in Vectashield (Vector Laboratories) on glass slides.
Slides were visualized with an Olympus BX61WI fluorescence con-
focal microscope employing a Hamamatsu Orca-ER C4742-80
camera.
GENERATION OF NCI H345 AND NCI H82 TUMOR XENOGRAFTS
Male nu/nu mice 6–7 weeks of age were purchased from the NCI.
NCI H345 and NCI H82 cells were trypsinized, concentrated
into growing medium by centrifugation (4–5× 107 cells/ml) and
injected subcutaneously in the lower right flank quadrant (1–
2× 107 cells/animal) using a 1-ml syringe and 22-gage needle.
Cells were allowed to generate tumor xenografts for 21 days (NCI
H345), and 14 days (NCI H82), before the initiation of the studies.
At these times, all of the mice receiving cells produced tumors that
ranged in length from 0.5 to 0.75 cm. For the following 3 days,
tumors were evaluated for tumor growth by measuring length,
width, and depth with a micrometer (Electronic Digital Caliper,
Fisher Scientific Inc.) and size expressed as the product of all three
parameters. Measurements were performed on mice anesthetized
with a mixture of isoflurane and oxygen (NCI 345), or without
anesthesia (NCI H82).
An Fab fragment of MAG-1 was generated and isolated using
Kit No. 448800 [Immunopure IgG1 Fab and F(ab′)2 preparation
kit] from Pierce Chemical Co. (Rockford, IL, USA). This com-
prised adding MAG-1 antibody (1–5 mg/ml) in cysteine-reduced
digestion buffer to a ficin-bound column and incubating for 3–5 h
at 40°C. Products were passed through a Protein A column and
the Fab fragment bound, then eluted and dialyzed.
CHX-A′′-DTPA coupling reagent was used to generate a chelat-
ing group for the Fab product, and 99Tc, generated through SnCl2
reduction from 99TcO−4 added. For imaging, athymic nude mice
received an intravenous injection of 99Tc-DTPA-CHX-A′′-Fab
MAG-1. Whole-body gamma camera scintigraphy of mice was
performed at 10 min, 1, 4, and 24 h post-injection. Images were
obtained with an E–Z hand-held gamma camera (Az-CA256AN)
of the Anzai Medical Co., Ltd. (Japan) and data recorded on a
dedicated computer.
TREATMENT WITH ANTIBODIES
NCI H345 tumor-bearing mice were divided into two groups of
four animals in one short-term treatment study on the effects
of 90Yttrium-labeled antibodies, two groups of four animals in a
second short-term treatment study on the effects of naked anti-
bodies, and two groups of four animals in a long-term treatment
study on the effects of naked antibodies. Animals were selected
to provide a similar range in tumor size for each grouping. For
each short-term study, group 1 comprised animals treated with
four intra-peritoneal (i.p.) injections of 50µl of saline vehicle
given on days 0, 2, 4, and 6. Animals of group 2 received four i.p.
injections of 50µCi (initially 20 mCi/mg protein) of 90Yttrium-
labeled MAG-1 (33) made up to 50µg with naked MAG-1 carrier
[~1.65 mg/kg body weight (BW)] in 50µl saline. The amount of
radiolabel and antibody employed was based on earlier studies by
us and others (33, 37). For the second short-term study, groups
2 comprised treatments on days 0, 2, 4, and 6, with 50µg/50µl
of naked MAG-1 (~1.65 mg/kg BW). Tumor volume was mea-
sured by micrometry and the BW of animals evaluated, daily, for
16 days. For the long-term study,animals were injected i.p. daily for
16 days with either saline vehicle (group 1), or with 100µg/50µl
(~3 mg/kg BW) naked MAG-1 (group 2). Tumor size and animal
BW were assessed daily over this period, and daily measurements
of tumor volume and BW were extended for the MAG-1-treated
group for an additional 20 days. Possible toxicity of treatment was
measured by examining major organs (liver, kidneys) and tumors
for necrotic changes at the end of the long-term study. For NCI
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H82 tumor-bearing mice, treatment was with 6.6 mg/kg BW of
MAG-1 given daily for 14 days.
Assessment of apoptosis in NCI H82 tumors
A number of fine needle biopsies were performed on one MAG-
1-treated (~3 mg/kg BW/day) and one saline-treated NCI H82
tumor in nu/nu mice, and tissues obtained were analyzed by West-
ern Analysis for increases in cleaved (89 kDa) PARP as an index of
apoptosis. Biopsies were taken using a 1′′ 18-gage needle attached
to a 1-ml syringe at times 0, 6, 24, 30, 48, and 54 h post-treatment
from animals under isoflurane anesthesia. These biopsies rou-
tinely yield ~20 mg of tissue, and these tissues were spun free
from needle and syringe and extracted for protein using SDS lysis
buffer [2% SDS, 1% 2′-(N -cyclohexylamino)ethane sulfonic acid
(CHES), 1% glycerol] in the presence of anti-protease cocktail
(Sigma-Aldrich, St. Louis, MO, USA). Samples containing similar
amounts of total protein (~20µg) were separated on 12.5% gels
by SDS-PAGE (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3),
and then transferred onto Immobilon-P PVDF membrane (Mil-
lipore, Bedford, MA, USA) in the Tris-glycine buffer with 20%
methanol added, using the Mini-Protean 3 system (Bio-Rad, Her-
cules, CA, USA). Membranes were blocked using 5% BSA in Tris-
buffered saline with 0.1% Tween-20 (TBST), and relative amounts
of both intact (116 kDa) and Caspase-cleaved (89 kDa) PARP
were detected using a rabbit polyclonal antibody preparation from
Cell Signaling Technology (Danvers, MA, USA, see above). After
washing, a goat anti-rabbit HRP-conjugated secondary antibody
preparation was employed (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and detection was carried out using SuperSignal West
Dura Extended Duration substrate (Pierce Chemical Co., Rock-
land, IL, USA) and imaged using a FluorChem 8900 imager (Alpha
Innotech).
STATISTICAL ANALYSIS
Longitudinal growth data were evaluated by repeated measures
of analysis of variance. The independent variables were factors
for treatment group and time and for the interaction between
treatment and time. In all cases, our analysis focused on compar-
ing MAG-1 groups with the control groups. A two-sided p-value
<0.05 was considered statistically significant.
RESULTS
MAG-1 BINDS TO THE SURFACE OF SCLC CELLS
Indirect fluorescence and confocal microscopy at low tempera-
ture revealed that MAG-1 antibody clearly binds to the surface,
not only of NCI H345 cells, representing primary disease, but
also of NCI H82 cells, representing recurrent SCLC. This is illus-
trated for NCI H82 cells in Figure 1A. At elevated temperatures,
the antigen–antibody complex clearly relocated to inside of the
cells as cytoplasmic clusters (data not shown). No fluorescence of
cancer cells was obtained when MOPC21 antibody was used as
negative control.
MAG-1 TARGETS SCLC XENOGRAFTS IN MICE
Whole-body scintigraphy revealed that 20 h following i.p. delivery
of 99Tc-CHX-A′′-DPTA-Fab-MAG-1, radioactivity was located
chiefly in the tumor. As indicated in Figure 1B, 99Tc-CHX-A′′-
DPTA-Fab-MAG-1 clearly imaged the H345 tumor in the tumor-
bearing nude mouse with an estimated tumor to normal tissue
ratio that ranged from 3.5 to >20.
SHORT-TERM TREATMENT WITH NAKED MAG-1 ANTIBODY AS WELL
AS 90YTTRIUM-LABELED MAG-1 DECREASES THE RATE OF GROWTH OF
NCI H345 SCLC TUMORS
Tumors treated over 6 days with either native MAG-1 (50µg,
n= 4) or 90Yttrium-labeled MAG-1 (50µCi/µg protein with
50µg MAG-1 carrier, n= 4) underwent a significant decrease in
their rate of growth to ~50% of control rates during the treat-
ment period. Since results with MAG-1 were similar with each
short-treatment method, and since each treatment comprised
the same total amount of antibody, we believe that most of the
inhibitory effects seen by the end of the treatment with radiola-
bel were due to naked antibody. Nevertheless, while similar results
were obtained with both treatments, there was still a marginally
larger effect with radiolabeled antibody, which indicates that more
pronounced effects could be obtained by targeting with sufficient
amounts of MAG-1 modified with a lethal label. Results are shown
in Figures 1C,D below, and are expressed as the percentage change
in tumor size with treatment. During the period of observation,
the tumors of both saline control groups increased in size by at least
nine-times (>900%), while the 90Yttrium-labeled MAG-1 group
and native MAG-1 group both increased by only ~4-times. In each
study, there was a clear significant difference between saline and
MAG-1 antibody treatments (p< 0.005 and p< 0.01).
EXTENDING AND INTENSIFYING NATIVE MAG-1 TREATMENT FURTHER
IMPAIRS NCI H345 TUMOR GROWTH
The influence on NCI H345 tumors of increasing the dose and
frequency of native antibody to 100µg/day (~3 mg/kg BW) and
extending the treatment period from 6 to 16 days is shown in
Figure 1E. This MAG-1 treatment of tumors (n= 4) caused a
further reduction in growth rate to approximately one-quarter
(~25%) of the growth rate and doubling time for saline-treated
animals (p< 0.001). Saline-treated tumors (n= 4) showed rapid
growth so that at 16 days, they were about 10 times their size at the
start of the study.
TREATMENT WITH NATIVE MAG-1 IMPAIRS NCI H82 TUMOR GROWTH
NCI H82 is a variant cell line representing recurrent disease.
Growth of tumor xenografts derived from this cell line was also
impaired by treatment with native MAG-1 (n= 8) compared to
saline treatment (n= 8) or treatment with MOPC21 (n= 8), a
mouse immunoglobulin of the same sub-class (Figure 1H). The
growth rate of MAG-1-treated tumors was about one-half of that
of saline or MOPC21 treated tumors (p> 0.01), with a ~3-fold
increase in the initial tumor doubling time.
MAG-1 APPEARS TO INCREASE NCI H82 TUMOR APOPTOSIS
The amount of Caspase-cleaved PARP relative to total PARP, in
tissues obtained through tumor needle biopsies, was employed
as an index of apoptosis. From our initial studies comparing
saline treated to MAG-1-treated tumor, apoptosis due to anti-
body increased following commencement of treatment from ~3%
at 6 h, through ~40% at 24 h, to a maximum of ~55% at 30 h.
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FIGURE 1 | (A) Immunofluorescence and confocal imaging of NCI H82
cells with MAG-1 and MOPC21 (center insert); the blue staining of the
confocal image is DAPI; (B) in vivo imaging of NCI H345 tumor in nu/nu
mouse with 99Tc-DTPA-CHX-A′′-Fab MAG-1 at 20 h after administration of
label; (C) treatment of NCI H345 tumor in nu/nu mice with 50µCi
90Y-DPTA-CHX-A′′-MAG-1 (50µg/30 g body weight total antibody) given
alternate days (×4). Values expressed as % change in mean tumor size
(±SEM) from day 0 (n=4); (D) treatment of NCI H345 cells tumors in
nu/nu mice with native MAG-1 (50µg/g body weight) given alternate days
(×4). Values expressed as % volume change (±SEM) from day 0 (n=4);
(E) treatment of NCI H345 cells tumors in nu/nu mice with native MAG-1
(100µg/30 g body weight) given each day for 14 days. Values expressed as
% change (±SEM) from day 0 (n=8); (F) histology of control H345 tumor
(G) and MAG-1-treated NCI H345 tumor; (H) treatment of NCI H82 tumor
in nu/nu mice with native MAG-1, MOPC21 isotype antibody control, or
saline vehicle. Antibody (200µg/30 g body weight) was given daily for
14 days. Values expressed as % volume change for 14 days (n=8) (↑, end
of treatment).
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MAG-1 ANTIBODY IS SELECTIVELY HARMFUL TO TUMORS
For both the short-term and long-term studies, fixed tissue exam-
ination revealed there were no structural or pathological changes
induced in normal tissues by treatments with naked or 90Y-labeled
MAG-1, while a substantial amount (30–50%) of necrosis was
present in MAG-1-treated tumors compared with saline-treated
tumors where there were little to no (<5%) necrotic changes
evident. Examples of MAG-1-treated and saline-treated tumors
of the extended study, stained with hematoxylin, are shown in
Figures 1F,G.
ANTIBODY TREATMENTS HAVE NO APPARENT EFFECTS ON ANIMAL
WELL-BEING
Treatment with either naked MAG-1 or 90Y-labeled MAG-1 had
no apparent effect on the well-being of tumor-bearing animals as
judged by their behavior and BWs. There were no discernible dif-
ferences in BW changes of the period of observation between any
of the groups. There was no observable pathology of the livers and
kidney from short-term MAG-1 and 90Y-labeled MAG-1-treated
animals. In addition, histological evaluation of organ tissues such
as the liver and kidneys revealed there was no damage to these tis-
sues by extensive treatment with native MAG-1. Since there is only
50% homology between the mouse and human pro-vasopressin
18-mer C-terminus, we generated polyclonal antibodies in mice
against the mouse peptide to look for possible negative con-
sequences. Two of three mice immunized with the C-terminal
18-mer of mouse pro-vasopressin produced high titer antibodies
(>1:10,000) against this peptide. However, the presence of these
polyclonal antibodies did not appear to disturb in any way the
physiology or behavior of animals.
DISCUSSION
The data presented here illustrates that a monoclonal antibody,
MAG-1, can target tumor xenografts of SCLC in nu/nu mice,
and significantly impair the growth of such tumors. MAG-1 is
a mouse IgG1 immunoglobulin, and was raised against the C-
terminal 18 residues of human pro-vasopressin earlier shown by
us to be a surface marker of most, or all, small-cell tumors (20,
31, 32). Targeting was directed to the surface of tumor cells as
shown by confocal microscopy, and targeting of tumor xenografts
seemed to be specific from 99mTechnetium-labeled Fab imaging
studies. The fourfold reduction in growth rate by MAG-1 anti-
body at ~3 mg/kg BW, of xenografts derived from a classical cell
line representing primary SCLC tumors strongly suggests that a
humanized version of MAG-1 could be used in conjunction with
chemotherapy to more effectively treat the primary form of this
disease in patients. Such antibody–chemotherapy combinations
have proved to be very effective in breast cancer with Herceptin
where disease recurrence was reduced by half of that occurring
following chemotherapy alone (38). The marker targeted by MAG-
1 antibody is most importantly present on recurrent disease for
which there is currently no effective treatment. While treatment
with native MAG-1 seems to be more effective on tumors derived
from the classical cell line NCI H345 representing primary dis-
ease, it still has a significant effect on tumors derived from the
variant cell line NCI H82, obtained from a pleural effusion and
representing recurrent SCLC (39, 40). This effect was to increase
tumor doubling time three to fourfold over controls (p< 0.01).
Since a dose response effect of the antibody on growth, was seem-
ingly demonstrated at least for NCI H345 tumors, it is possible that
higher amounts of antibody than used here could have even greater
impacts on the growth of SCLC tumors representing both primary
and recurrent disease. Clearly, significant apoptosis was demon-
strated by the pathology in fixed tissues of residual tumors from
treatment with higher amounts of MAG-1 antibody. In the case
of NCI H82 tumor, antibody-induced apoptosis in initial stud-
ies was also demonstrated by increased PARP cleavage. Although
the mechanism for the effectiveness of MAG-1 is still not known
beyond this apoptosis, the marker-antibody complex was shown
to become internalized.
While most of the reduction in tumor growth observed was
by native MAG-1 antibody alone, there was however, a marginally
greater effect seen when MAG-1 was attached to 90Yttrium. This
finding indicates that this and other modified forms of the anti-
body might have an additional impact in potential future targeted
treatments.
Native MAG-1 has already been shown by us to prevent growth
and shrink xenografts of estrogen-responsive and triple-negative
human breast cancer (33). Effects of MAG-1 treatments were more
dramatic than those shown here for SCLC, and were accomplished
with the smaller amounts of antibody than used for treatment of
SCLC (~1.5 mg/kg BW). Additionally, most treated breast tumors
failed to rebound after treatment stopped, while in most cases the
major negative effects of MAG-1 on SCLC growth occur during
an early stage of treatment. Tumors representing recurrent dis-
ease then typically increased their growth rate to one exhibited
by controls treated by saline vehicle or with ubiquitous MOPC1
antibody. Nevertheless, the initial influences on growth reduction
observed in this study are substantial given that there is currently
no successful therapy for recurrent SCLC.
This raises the possibility of a humanized form of the MAG-1
antibody to be used in the development of therapies against this
recurrent disease. The actions of MAG-1 antibody are particu-
larly relevant since we have previously shown the surface antigen
on tumors recognized by the antibody can be effectively targeted
in patients (30). This antibody targeting of pro-vasopressin was
found to be specific for tumors, and it was later shown that MAG-
1 did not react with any of an array representing 66 different
normal human tissues (31). MAG-1 in mice is also tumor selec-
tive and treatment with this antibody had no deleterious effects
on normal tissues of these animals. However, because this latter
finding could have been, in part due to a failure of MAG-1 to rec-
ognize mouse pro-vasopressin, we generated polyclonal antibodies
in mice against the C-terminal region of the mouse molecule. The
presence of high titers of these polyclonal antibodies (effective in
radioimmunoassay at serum dilution >1:40,000) failed to affect
mice in any way, including an absence of diabetes insipidus.
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